Although it is a reasonable assumption that there might be carcinogenic effects, still there is no evidence that GH treatment in young patients with growth disorders actually results in an increased risk of developing cancer relative to that expected in the normal population (13). The gene discussed is GH1; the disease is hereditary endocrine growth disease.